BackInhibikase Therapeutics Overview

Inhibikase Therapeutics Net Income

Profitability analysis for IKT.

Quarterly Net Income

-$16.38M
↓ 19.75% YoY

As of Mar 2026

Annual Net Income (TTM)

-$50.96M
↓ 39.43% YoY

Trailing 12 months ending Mar 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin